No­vo fur­ther boosts ev­i­dence for semaglu­tide’s heart ben­e­fits be­yond weight loss: #ACC24

No­vo Nordisk’s semaglu­tide has hit a pair of pri­ma­ry end­points in a late-stage test in pa­tients with a trio of car­diometa­bol­ic con­di­tions, bol­ster­ing the com­pa­ny’s ef­forts to ex­pand its ter­ri­to­ry in obe­si­ty and type 2 di­a­betes to oth­er, re­lat­ed in­di­ca­tions.

Show­ing that semaglu­tide can im­prove car­dio­vas­cu­lar out­comes can help No­vo fur­ther boost the drug’s re­im­burse­ment prospects. In March, the block­buster drug won FDA ap­proval to re­duce the risk of car­dio­vas­cu­lar death, heart at­tack and stroke in obese or over­weight heart dis­ease pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER